Puma Biotechnology Stock Price - PBYI

0.01 (0.08%)
Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
Canadian Level 1 + USA
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Puma Biotechnology Inc PBYI NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
1.04 8.49% 13.29 12.0804 13.42 12.25 12.25 16:35:01
Bid Price Ask Price Spread Spread % News
13.16 13.30 0.14 1.05% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
8,986 1,108,860 $ 12.90 $ 14,299,101 2,490,326 5.80 - 43.90
Last Trade Time Type Quantity Stock Price Currency
16:34:16 formt 100 $ 13.30 USD

Puma Biotechnology Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 520.97M 39.20M $ -113.58M -2.99 -6.75 34.60M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% -1.00 11.80%

more financials information »

Puma Biotechnology News

Loading Messages....

Latest PBYI Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical PBYI Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week12.5013.4211.7012.371,166,4560.796.32%
1 Month9.5615.007.7012.272,847,8823.7339.02%
3 Months9.5515.007.3510.322,184,0653.7439.16%
6 Months9.5315.005.809.761,768,9743.7639.45%
1 Year27.6443.905.8014.661,515,371-14.35-51.92%
3 Years40.25136.905.8040.271,191,917-26.96-66.98%
5 Years31.25136.905.8040.131,172,150-17.96-57.47%

Puma Biotechnology Description

Puma Biotechnology is a biotechnology company focused on developing novel therapeutics for the treatment of cancer. Puma licenses the commercial rights to its current drug candidates. The company expects to augment its product pipeline by acquiring, through license or otherwise, additional drug candidates for research and development and potential commercialization. In evaluating potential drug candidates, Puma employs disciplined decision criteria favoring drug candidates that have undergone at least some clinical study.

Your Recent History
Puma Biote..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.